784
Views
114
CrossRef citations to date
0
Altmetric
Research Article

In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes

, , , , , & show all
Pages 847-856 | Received 23 Dec 2010, Accepted 01 Sep 2011, Published online: 24 Oct 2011
 

Abstract

Gold nanorods (Au-NRs) have attracted enormous interest due to their size and unique optical properties. Many studies have demonstrated their use in biomedical systems. However, their potential toxicity is not fully understood. This study evaluated the effects of the Au-NRs (15 nM × 64 nM) coated with CTAB (cetyltrimethylammonium bromide) or PEG (polyethylene glycol) in human erythrocytes on the induction of haemolysis and erythroptosis. In our study, erythroptosis (also known as eryptosis) was determined systematically through the measurement of feature events of apoptosis by flow cytometry. We found that the CTAB- and PEG-coated Au-NRs up to 0.5 nM did not cause severe haemolysis. However, the CTAB-Au-NRs were more toxic than the PEG-Au-NRs. The toxicity of the CTAB-Au-NRs was largely due to the CTAB residues from desorption or incomplete purification. Mechanistically, cytosolic Ca2+ ions seem to be the key mediator in the eryptosis/erythroptosis mediated by the CTAB or CTAB-Au-NRs while caspase-3 and reactive oxygen species did not contribute much to the process.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.